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LIABILITY OF BIRTH CONTROL
PILL MANUFACTURERS
The oral contraceptives present society with problems unique in
the history of human therapeutics. Never will so many people
have taken such potent drugs voluntarily over such a protracted
period for an objective other than the control of disease.'
Eight and one-half million women in this country alonc ingest
oral contraceptives in an effort to control their reproductive lives.' As
a result of taking these pills an unknown number of women have died
or suffered permanent injury.3 Some of these deaths and injuries are
the subject of current litigation.
4
The birth control pill is a prescription drug.' Prescription drugs
are distinguishable from other products because of the high degree of
regulation and control exercised by the Food and Drug Administra-
tion (FDA) over their production and marketing.' Unlike most other
prescription drugs, however, the pill presents a special case in that
1. FDA, REPORT ON THE ORAL CONTRACEPTIVES BY THE ADVISORY COMM.
ON OBSTETRICS AND GYNECOLOGY 1 (1966).
2. FDA, SECOND REPORT ON THE ORAL CONTRACEPTIVES BY THE ADVISORY
COMM. ON OBSTETRICS AND GYNECOLOGY 3 (1969).
3. In a study based upon California data, Dr. Harold Williams estimates that
there are at least 3,000 deaths of young women per year and 30,000 serious, nonfatal
illnesses due to the use of birth control pills. H. WILLIAMS, THE PILL IN NEW
PERSPECTIVE 16, 131-38 (1969) [hereinafter cited as WILLIAMS].
4. Although at least 200 suits involving oral contraceptives are pending against
drug manufacturers, only three known verdicts have gone against the companies. The
drug firms have prevailed in six cases that have been decided at the trial court level.
American Medical News, Nov. 29, 1971, at 10, col. 1. See generally Barrett,
Product Liability and the Pill, 19 CLEVE. ST. L. REV. 468 (1970), for an excellent
discussion of medical testimony presented at the trials of the first birth control pill
cases.
5. The term prescription drug includes "[a] drug intended for use by man
which-
"(A) is a habit-forming drug to which section 352(d) of this title applies; or
"(B) because of its toxicity or other potentiality for harmful effect or the
method of its use, or the collateral measures necessary to its use, is not safe for use
except under the supervision of a practitioner licensed by law to administer such drug;
or
"(C) is limited by an approved application under section 355 [relating to "new
drugs"] of this title to use under the professional supervision of a practitioner licensed
by law to administer such drug .... ." 21 U.S.C. § 353(b)(1) (1970).
6. The basic regulation of drugs in the United States is pursuant to the Federal
Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301-92 (1970).
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consumer demand for the drug has prompted its use more often than
the doctor's advice.' A study of the development and marketing of
oral contraceptives will indicate that drug manufacturers should bear
the burden for injuries and loss of life inflicted by their product.
The Emergence of the Pill Controversy
G. D. Searle & Co., the manufacturer of the first oral contra-
ceptive, Enovid, received approval from the FDA in June of 1960 to
market the drug." Incidents of thromboembolic phenomena (blood
clotting) were thereafter reported with increasing frequency.' An ad-
visory committee of experts reported to the FDA in 1963, however,
that in their opinion, "no significant increase in the risk of thrombo-
embolic death from the use of Enovid in this population group has
been demonstrated."' 10 The data upon which this committee relied
has been criticized severely." Nevertheless, with this questionable
assurance of safety, the FDA continued to approve new pills for mar-
keting.
In April of 1965, the first two sequential birth control pills were
approved by the FDA.' 2 In 1966 another committee of experts is-
sued a report calling for planned studies on the side effects of birth
control pills. 3 Although the estimated number of users in the United
States at this time was over five million women, 14 no government
7. See note 90 and accompanying text infra.
8. Hearings on Present Status of Compet:tion in the Pharmaceutical Industry
Before the Subcomm. on Monopoly of the Senate Comm. on Small Business, 91st
Cong., 2d Sess., pt. 16, at 6787 (1970) (testimony of Dr. Charles C. Edwards, Com-
missioner, Food and Drug Administration) [hereinafter cited as Nelson Comm. Hear-
ings].
9. FDA, REPORT ON ENOVID BY THE AD Hoc COMM. FOR THE EVALUATION
OF A POSSIBLE ETIOLOGIC RELATION WITH THROMBOEMOLIC CONDITIONS (1963) in
Nelson Comm. Hearings, supra note 8, at 7235, 7237.
10. FDA, FINAL REPORT ON ENOVID BY THE AD Hoc COMM. FOR THE EVALUA-
TION OF A POSSIBLE ETIOLOGIC RELATION WITH THROMBOEMBOLIC CONDITIONS 14
(1963) in Nelson Comm. Hearings, supra note 8, at 7247.
11. L. LASAGNA, LIFE, DEATH AND THE DOCTOR (1968). Dr. Lasagna of Johns
Hopkins charges that the Wright Committee's reliance on the fatality records in the
files of G.D. Searle & Co. was an "appalling mistake," Id. at 142.
12. Testimony of Dr. Edwards in Nelson Comm. Hearings, supra note 8, at
6787. Sequential birth control pills are composed of estrogen tablets for the first 15
days of medication, followed by five days of a mixture of estrogen and a progesterone.
Proponents of sequential pills claim they simulate the natural cycle. Davis & Fugo,
Drugs in Obstetrics and Gynecology, in DRuGs OF CHOICE 1968-69, 618 (W. Modell
ed. 1967).
13. FDA, REPORT ON ORAL CONTRACEPTIVE BY THE ADvISORY COMM. ON OB-
sTETCS AND GYNECOLOGY 12 (1966).
14. Id. at 5.
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funds had ever been allocated to a comprehensive study of the effects
of birth control pills, and no funds were allocated as a result of the
facts revealed by this report. 15 There is some evidence that manu-
facturers of the pill may have discouraged reports of adverse reactions
to the pill, and usually death alone prompted independent investiga-
tion by the drug manufacturer. 16
Dr. Charles C. Edwards, Commissioner of the FDA, acknowl-
edged the harm of overzealous marketing:
By 1966 competition in the oral contraceptive market had
resulted in exaggerated and misleading claims. Advertising to
physicians and some promotion materials attempted to establish
ideas of product superiority which in our judgment had no scien-
tific basis. 17
Publications extolling the wonders of the birth control pills were reach-
ing the consumer public as well as the medical profession. Articles as-
suring women that the pill was safe and effective appeared in such
popular periodicals as Redbook and Parent's Magazine,' 8 and the num-
ber of users continued to rise.' 9
In 1968 a British study of the pill concluded that
From [our] data it is calculated that the risk of hospital admission
for venous thromboembolism is about nine times greater in women
who use oral contraceptives than in those who do not.
20
Based on the British studies and the increasing number of cases of
15. H. MINTZ, "THE PILL" AN ALARMING REPORT 53 (1969) [hereinafter cited
as MINTZ].
16. "Some of the investigations of deaths were associated with repeated visits
and telephone calls to physicians whose patients had died. Other investigations were
quite cursory and reflected considerable concern over the company's image with the
physician. 'He cannot be irritated-it's bad for our business relationships.'" Kohl,
Review of the Procedures and Reports of the Pharmaceutical Companies Concerned
With the Manufacture and Sale of the Oral Contraceptives in FDA, REPORT ON THE
ORAL CONTRACEPTIVE BY THE ADVISORY COMM. ON OBSTETRICS AND GYNECOLOGY,
app. 6, at 61 (1966).
17. Testimony of Dr. Edwards in Nelson Comm. Hearings, supra note 8, at
6788.
18. E.g., Hellman, Doctor's View of Birth Control Pills, REDBOOK, Apr. 1969,
at 132 (Dr. Louis M. Hellman was chairman of the FDA's Advisory Committee on
Obstetrics and Gynecology); Langmyhr, How Safe Is the Pill? PARENT'S MAGAZINE,
Oct. 1967, at 58 (Dr. George Langmyhr was medical director of Planned Parenthood-
World Population and formerly associated with Ortho Pharmaceutical Corp., a birth
control pill manufacturer). See generally MINTZ, supra note 15, at 22-37, for a com-
prehensive listing of books, articles and television programs about birth control pills.
19. The estimates for use of birth control pills were 150% higher in 1969 (8.5
million users) than in 1965. FDA, SECOND REPORT ON THE ORAL CONTRACEPTIVES
BY THE ADVISORY COMM. ON OBSTETRICS AND GYNECOLOGY 3 (1969).
20. Vessey & Doll, Investigation of Relation Between Use of Oral Contraceptives
and Thromboembolic Disease, BRITISH MED. J., Apr. 27, 1968, at 199, 205.
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thromboembolic diseases associated with women taking the pill, the
FDA issued a warning in June of 1968 to the physicians in this coun-
try, advising them of the British findings.21 At the same time, how-
ever, the drug companies were making efforts to allay fears justifiably
generated by the findings of the British study.22
There were increased reports in 1969 of deaths and serious ill-
ness caused by birth control pills,2 3 and the FDA issued another warn-
mg to doctors.24  The controversy surrounding birth control pills mten-
sified in early 1970 when United States Senator Gaylord Nelson held pub-
lic hearings on the use of birth control pills. On the final day of the
hearings, the FDA announced that it would issue leaflets to accom-
pany all birth control pills to warn women users of the hazards as-
sociated with the pill.25 FDA Commissioner Edwards had found that
"the information being supplied to the patient in the case of the oral
contraceptive [was] insufficient "26 He submitted to the Nel-
son Committee a 600 word statement, explaining the risks of pill in-
gestion in lay language. Commissioner Edwards emphasized that the
leaflet27 was merely a "reminder," designed to reinforce the informa-
tion provided the patient by her doctor. What Commissioner Ed-
wards did not mention, although it had been reported in testimony be-
fore the hearing, was that a then current Gallup survey of women re-
21. Letter from Dr. James L. Goddard, Commissioner, Food and Drug Admin-
istration, June 28, 1968 in Nelson Comm. Hearings, supra note 8, at 7022.
22. E.g., Drill, Oral Contraceptives and Thromboembolic Disease, 206 J.A.M.A.
77 (1968). Dr. Victor A. Drill was the director of biological research for G.D.
Searle & Co. This article provides evidence that the birth control pill is not a cause of
thrombophlebitis.
23. Testimony of Dr. Edwards im Nelson Comm. Hearings, supra note 8, at
6789-93.
24. Letter from Dr. James L. Goddard, Commissioner, Food and Drug Admin-
istration, Jan. 12, 1970, in Nelson Comm. Heanngs, supra note 8, at 7017.
25. See note 29 & accompanying text infra.
26. Testimony of Dr. Edwards in Nelson Comm. Hearings, supra note 8, at 6800.
27. "What You Should Know About Birth Control Pills (Oral Contraceptive
Products)
"All of the oral contraceptive pills are highly effective for preventing preg-
nancy, when taken according to the approved directions. Your doctor has taken
your medical history and has given you a careful physical examination. He has dis-
cussed with you the risks of oral contraceptives, and has decided that you can take
this drug safely.
'This leaflet is your reminder of what your doctor has told you. Keep it
handy and talk to lm if you think you are experiencing any of the conditions you
find described.
"A Warning About 'Blood Clots'
"There is a definite association between blood-clotting disorders and the use
of oral contraceptives. The risk of this complication is six times higher for users
than for non-users. The majority of blood-clotting disorders are not fatal. The
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vealed that two-thirds of pill taking women had never been warned of
estimated death rate from blood-clotting in women not taking the pill is one in 200,000
each year; for users, the death rate is about six in 200,000. Women who have or
who have had blood clots in the legs, lung, or brain should not take this drug. You
should stop taking it and call your doctor immediately if you develop severe leg or
chest pain, if you cough up blood, if you experience sudden and severe headaches, or
if you cannot see clearly.
"Who Should Not Take Birth Control Pills
"Besides women who have or who have had blood clots, other women who
should not use oral contraceptives are those who have serious liver disease, can-
cer of the breast or certain other cancers, and vaginal bleeding of unknown cause.
"Special Problems.
"If you have heart or kidney disease, asthma, high blood pressure, diabetes,
epilepsy, fibroids of the uterus, migraine headaches, or if you have had any prob-
lems with mental depression, your doctor has indicated you need special supervi-
sion while taking oral contraceptives. Even if you don't have special problems, he
will want to see you regularly to check your blood pressure, examine your breasts,
and make certain other tests.
When you take the pill as directed, you should have your period each month.
If you miss a period, and if you are sure you have been taking the pill as directed,
continue your schedule. If you have not been taking the pill as directed and
if you miss one period, stop taking it and call your doctor. If you miss two periods,
see your doctor even though you have been taking the pill as directed. When you
stop taking the pill, your periods may be irregular for some time. During this time
you may have trouble becoming pregnant.
"If you have had a baby which you are breast feeding, you should know
that if you start taking the pill its hormones are in your milk. The pill may
also cause a decrease in your milk flow. After you have had a baby, check with your
doctor before starting to take oral contraceptives again.
"What to Expect
"Oral contraceptives normally produce certain reactions which are more fre-
quent the first few weeks after you start taking them. You may notice unexpected
bleeding or spotting and experience changes in your period. Your breasts may feel ten-
der, look larger, and discharge slightly. Some women gain weight while others lose it.
You may also have episodes of nausea and vomiting. You may notice a darkening of
the skin in certain areas.
"Other Reactions to Oral Contraceptives
"In addition to blood clots, other reactions produced by the pill may be seri-
ous. These include mental depression, swelling, skin rash, jaundice or yellow pig-
ment in your eyes, increase in blood pressure, and increase in the sugar content
of your blood similar to that seen in diabetes.
"Possible Reactions
"Women taking the pill have reported headaches, nervousness, dizziness, fa-
tigue, and backache. Changes in appetite and sex drive, pain when urinating, growth
of more body hair, loss of scalp hair, and nervousness and irritability before the
period also have been reported. These reactions may or may not be directly re-
lated to the pill.
"Note About Cancer
"Scientists know the hormones in the pill (estrogen and progestrone) have
caused cancer in animals, but they have no proof that the pill causes cancer in
humans. Because your doctor knows this, he will want to examine you regularly.
[Vol. 23
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possible hazards by their physicians.2"
Despite this lack of adequate warnings by physicians, the 600
word draft originally given the Nelson Committee was reduced to a 155
word warning statement.2 9 The final version mentioned only the in-
creased possibility of blood clotting, without warning, as the original
did, that the risk of clotting to women taking the pill would be six
times greater than to nonusers. Deleted from the original warning were
other possible pill consumption reactions including mental depression,
swelling, skin rash, jaundice, high blood pressure, and elevation of
blood sugar levels. Omitted also in the revised warnings were state-
ments that women with liver disease, cancers, unexplained vaginal
bleeding, heart or kidney diseases, high blood pressure, diabetes, epi-
lepsy, fiberous tissue in the uterus, migraine headaches, or emotional
problems should not take the pill.
The medical profession acted in similar disregard for the welfare
of pill-consuming women. Soon after the FDA released the original
"Remember
"While you are taking -, call your doctor promptly if you notice any un-
usual change in your health. Have regular checkups and your doctor's approval for
a new prescription." Id. at 6800-01.
28. Poll on the Pill-18 Percent of U.S. Users Have Recently Quit, NEWSWEEK,
Feb. 9, 1970, in Nelson Comm. Hearings, supra note 8, at 6628.
29. Compare note 27 with 21 C.F.R. § 130.45(d) (1) (1971), which requires





"Do Not Take This Drug Without Your Doctor's Continued Supervision.
'The oral contraceptives are powerful and effective drugs which can cause side
effects in some users and should not be used at all by some women. The most
serious known side effect is abnormal blood clotting which can be fatal.
"Safe use of this drug requires a careful discussion with your doctor. To assist
him in providing you with the necessary information,
(Firm Name)
has prepared a booklet (or other form) written in a style understandable to you as
the drug user. This provides information on the effectiveness and known hazards of
the drug including warnings, side effects and who should not use it. Your doctor
will give you this booklet (or other form) if you ask for it and he can answer any
questions you may have about the use of this drug.
"Notify your doctor if you notice any unusual physical disturbance or dis-
comfort." The second public draft of the FDA warning was a 120 word state-
ment which contained some warnings in addition to the basic warning of abnormal
blood clotting. Included in this statement was a caution to "[niotify- your doctor if
you notice any of the following: 1. Severe headache. 2. Blurred vision. 3. Pain
in the legs. 4. Pain in the chest or unexplained cough. 5. Irregular or missed periods."
35 Fed. Reg. 5962 (1970).
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600 word warning, an official American Medical Association statement
proclaimed that
the medical profession regards the pill, in most cases, as a con-
venience rather than a traditional medication and hence the pa-
tient must bear her share of the legal and moral responsibility for
taking it.30
Several months later, the American Medical Association decried the
proposed warning leaflet as "an intrusion upon the patient-physician
relationship."'" This pressure from the medical profession and drug
manufacturers may have resulted in a much diluted warning statement.
In summary, although blood clotting associated with the pill was
ascertainable after its marketing, 32 both the manufacturers and the
FDA refused to acknowledge the association between the pill and
serious blood clotting. Only after a British study, initiated to deter-
mine the degree of association, demonstrated the causal connection be-
tween blood clotting and the pill, did the FDA issue a warning to doc-
tors of the dangers of the pill. The pill manufacturers did not relay
this warning to the women consuming the pill but continued their cam-
paign in the mass media extolling the virtues of the pill. Women
were informed of the pill's effectiveness in preventing pregnancy with-
out being told of the concomitant risks of ingesting the pill. Only
after the well publicized Senate hearings concerning use of the pill did
the FDA require pill manufacturers to warn users of the pill of the
risks involved.
The Role of the FDA
All drugs marketed in the United States are subject to regulation by
the FDA.3 Included are both prescription 4 and proprietary or patent
drugs sold over the counter.3 Pursuant to its regulatory authority, the
FDA requires the drug manufacturer to submit data regarding the ef-
ficacy and safety of the drug before it will approve the drug for gen-
eral distribution.
6
When the pharmacological potential of a chemical compound is
discovered, drug manufacturers follow a standard set of procedures to
develop and test their product. The first step is "screening," a proced-
ure involving laboratory tests on animals or human tissue in test tubes
to determine harmful side effects and effectiveness, and to predict
30. Science News, March 14, 1970.
31. Cohn, AMA Pledges All-Out Fight Against Birth-Pill Warning, Washington
Post, June 24, 1970, at 8, col. 4.
32. MINTz, supra note 15, at 46.
33. 21 U.S.C. §§ 301-92 (1970).
34. Id. § 353.
35. Id. § 321(g)(2).
36. Id. § 355(b).
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human tolerance.17  The second step is an application to the FDA for
permission for the manufacturer to test the drug on human beings."8
Third, tests are conducted to determine the effectiveness of the drug.
These tests usually involve patients suffering from the particular ill-
ness sought to be treated and attention is paid to side effects 9 and
contraindications.4 In the case of contraceptive pill testing, however,
healthy women were the experimental subjects, for there was no "di-
sease" to be cured. The fourth step involves field trials by private doc-
tors using their own patients as subjects and reporting data back to
the drug manufacturer.4 1 Finally, an application is made to the FDA
for permission to market the drug.42  The FDA requires a report of all
significant data.collected by the manufacturer in the new drug appli-
cation.43  Thus, the drug companies have complete control over what
data is submitted to the FDA in their applications, and the FDA has
no staff to recheck any of the drug company information.44
Criticism of the manufacturers of birth control pills, however, has
not focused on charges of falsified or tailored research data.43  Rather,
37. DeHaen, Drug Development, MEDiCAL SCMNcE Nov. 1963, at 19. See
generally Trout, Genesis of a New Drug, in DRUG LABILrry LmGATION 52 (E. Sha-
piro, R. Needham & J. Feldman, eds. 1967) [hereinafter cited as Trout].
38. This is an Investigational New Drug (IND) Application and the FDA re-
quirements are detailed. See 21 C.F.R. § 130.3 (1971), Forms FD 1571-73, prom-
ulgated pursuant to 21 U.S.C. § 355(i) (1970). At the time birth control pills were
being tested for marketing, however, application for testing on humans to the FDA was
not a requirement. 21 U.S.C. § 355(i) '(1958), as amended, 21 U.S.C. § 355(i)
(1970).
39. Defined as "[a] consequence other than the one(s) for which an agent or
measure is used; sometimes applied to adverse effects produced by a drug, especially
on a system other than the one sought to be benefited by its administration." DoR-
LAND'S ILLUSTRATED MEDICAL DICTIONARY 1376 (24th ed. 1965).
40. Defined as "[a]ny condition, especially any condition of disease, which ren-
ders some particular line of treatment improper or undesirable." Id. at 340.
41. Trout, supra note 37, at 152.
42. 21 C.F.R. § 130.4(2), Form FD 356H-Rev. 1967 (1970), promulgated pur-
suant to 21 U.S.C. § 355(b) (1970).
43. Compare 21 Fed. Reg. 5577-78, Form FD 356-Rev. 1956 (1956), with 21
C.F.R. § 130.4(2), Form FD 356H-Rev. 1967 (1971). In 1960, when the first birth
control pills were approved for marketing by the FDA, the requirements for data on
the new drug application was much less detailed.
44. Wiley, The Analysis of Drugs, 16 FOOD DRUG Cosm. L.J. 733, 736 (1971).
Injuries caused by one of the most litigated prescription drugs, MER/29, might have
been prevented if the drug manufacturer had not falsified research results submitted
with their new drug application. The manufacturer of MER/29 was convicted of
making false 'statements to the FDA in their New Drug Application. Rheingold,
The MER/29 Story-An Instance of Successful Mass Disaster Litigation, 56 CALIF.
L. REv. 116 (1968).
45. See generally discussions of "rigged research" in Editorial, 265 N. ENoL. J.
MED. 1116 (1961); Medical Tribune, June 4, 1962, at 3.
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criticism has focused on the inadequacy of testing carried out prior to
marketing, the lackadaisical attitude of the FDA towards clearly in-
sufficient data and wide spread, inaccurate claims of safety made to
users.
4 6
Birth control pills should be distinguished from other prescription
drugs because the FDA procedures have not been judiciously applied
in the public interest and because pill manufacturers created consumer
demand. The drug manufacturer's liability may arise from the inade-
quate warning against known side effects, failure to provide direct
warnings to the pill consumer and strict liability.
Inadequate Warning of Known Side Effects
Warning to Medical Profession
A drug company has a duty to warn the prescribing doctor of
contraindications or side effects of the drug.47 Failure to give an ade-
quate warning is a breach of the manufacturer's duty of care under a
negligence theory.4 8 In prescription drug cases, the manufacturer is
required to exercise the skill of an expert in the business of manufac-
turing prescription drugs. 9 The duty involved necessitates giving a
reasonable warning, but not the best possible warning.50
Sterling Drug, Inc. v. Yarrow outlines the methods a drug manu-
facturer should use to communicate its product information to doctors:
(1) by "detail men", who are specially trained field representa-
tives engaged in selling and promoting the use of its products by
personal calls in which oral presentations are made and literature
and samples delivered,
(2) by listing drugs in an annually published advertising medium
known as Physicians' Desk Reference,
(3) by "product cards" which are mailed and distributed by de-
tail men to physicians and are available at medical conventions
and hospital exhibits, and
(4) by special letters mailed to physicians ["Dear Doctor" letters].51
46. WILLIAMS, supra note 3, at 53-125.
47. E.g., Basko v. Sterling Drug, Inc., 416 F.2d 417 (2d Cir. 1969) (Aralen);
Magee v. Wyeth Laboratories, Inc., 214 Cal. App. 2d 340, 29 Cal. Rptr. 322 (1963)
(Sparine); Bine v. Sterling Drug, Inc., 422 S.W.2d 623 (Mo. 1968) (Aralen). See
cases collected 79 A.L.R.2d 301 (1961) for liability of the drug manufacturer.
48. RESTATEMENT (SECOND) OF TORTS § 301 (1965); W. PROSSER, LAW OF
TORTS § 33, at 179 (4th ed. 1971).
49. Bine v. Sterling Drug, Inc., 422 S.W.2d 623 (Mo. 1968) (Aralen); Krug v.
Sterling Drug, Inc., 416 S.W.2d 143 (Mo. 1967) (Aralen).
50. Sterling Drug, Inc. v. Yarrow, 408 F.2d 978 (8th Cir. 1969) (Aralen);
Nolan v. Dillon, 261 Md. 516, 523, 276 A.2d 36, 40 (1971) (promozine hydrochlor-
ide).
51. 408 F.2d 978, 987 (8th Cir. 1969) (Aralen).
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The drug manufacturer must make a reasonable effort to communicate
any important information to satisfy the duty to provide an adequate
warning.52
The Use of "Detail Men"
Doctors rely on the "detail men" to give them accurate, up-to-date
information on drugs because doctors do not always have time to care-
fully read the detailed information which accompanies the drug. 3
In one birth control pill case, for example, the prescribing doctor ad-
mitted throwing most of the drug company's literature in his waste-
basket without reading it.5 Because of the heavy reliance doctors place
on detail men, false assurances of safety by the detail men may negate
the effect of the printed warnings.55 In Love v. Wolf5" the detail men
were instructed by the manufacturer to de-emphasize the harmful ef-
fects of the drug. While reversing judgment for the plaintiff on grounds
of prejudicial misconduct of counsel, the court held that the plaintiff
had proffered a prima facie case of the negligent failure to warn
based on the evidence of dilution of the warning.
5 7
The court in Sterling Drug, Inc. v. Yarrow 8 adopted a more de-
tailed standard of reasonableness for the requisite warning accompany-
ing a prescription drug. In Yarrow the manufacturer had changed
drug literature to reflect evidence of newly discovered side effects.
The court determined that under the circumstances of that case the
failure of the company to make any effort to instruct their detail men
to repeat the warning in the literature constituted a breach of the
duty to warn.59 It has also been held that the drug company sales-
man is expected to give warnings not contained in the literature ac-
companying a drug, if such warnings are appropriate. 60
As revealed by the Nelson Committee hearings, birth control
52. Id. at 991-92.
53. See id. at 990; Love v. Wolf, 226 Cal. App. 2d 378, 399, 38 Cal. Rptr. 183,
195 (1964) (chloromycetin). See Louisell, The Liability of Drug Manufacturers for
Drug Reactions, in DRuG L AwIITY LITIGATION 169 (E. Shapiro, R. Needham & J.
Feldman, eds. 1967).
54. Brief for Appellant at 89, Carmichael v. Reitz, 17 Cal. App. 3d 958, 95 Cal.
Rptr. 381 (1971) (Enovid).
55. Sterling Drug, Inc. v. Yarrow, 408 F.2d 978, 990 (8th Cir. 1969) (Aralen);
Love v. Wolf, 226 Cal. App. 2d 378, 399, 38 Cal. Rptr. 183, 195 (1964) (chloromy-
cetin).
56. 226 Cal. App. 2d 378, 38 Cal. Rptr. 183, 195 (1964) (chloromycetin).
57. Id. at 402, 38 Cal. Rptr. at 197.
58. 408 F.2d 987 (8th Cir. 1969) (Aralen).
59. Id. at 992.
60. Parke-Davis & Co. v. Stromsodt, 411 F.2d 1390, 1400 (8th Cir. 1969)
(Quadrigen).
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manufacturers gave written instructions which led salesmen to de-em-
phasize evidence that the pill increased chances of blood clotting.6'
Ambiguity in instruction, minimization of danger and false assurances
of safety by detail men should, in the appropriate case, extend liability
to the manufacturer for inadequate warnings.
The Use of the Dear Doctor Letter
According to FDA regulations, the manufacturer must send a
special letter to doctors warning of drug dangers-even those discov-
ered after the commencement of marketing. 62  In this connection, the
manufacturer's duty to warn of dangerous side effects is a continuing
duty. 63 Several of these special letters, called "Dear Doctor" letters,
have been issued by birth control pill manufacturers.64 The "Dear
Doctor" letter alone may not be sufficient warning if the detail men
does not repeat the warning.15 However, the "Dear Doctor" letter
itself may be deficient if it lacks "emphasis" and "attention inviting
qualities." 6  To satisfy the requirement of an adequate warning, the
"Dear Doctor" letter should be concise and must emphasize the dangers
of the drug.
The timeliness of the warning to the medical profession is also an
important element of the adequate warning. 7  In Basco v. Sterling
Drug, Inc.,68 one of a series of cases involving the drug Aralen, evi-
dence showed that the first notice of association of irreversible blind-
ness with Aralen appeared in a medical journal as early as 1957. De-
fendant had made an effort to warn the medical profession in 1960,
by revising its product literature to hint of danger, but had not sent a
"Dear Doctor" letter until 1963. The court held that the issue of
the timeliness of the warning should be submitted to the jury.
This doctrine is equally valid in oral contraceptive cases, although
the question has not yet been litigated. In the only birth control pill
case where evidence was considered in an appellate court decision, evi-
61. Letter from W. L. Searle, vice president, marketing, G.D. Searle & Co., to
drug salesmen, Aug. 9, 1962, in Nelson Comm. Hearings, supra note 8, at 6272.
62. 21 C.F.R. §§ 130.9(a)(5), 130.13(2)(7) (1971).
63. E.g., Schenebeck v. Sterling Drug, Inc., 423 F.2d 919, 922 (8th Cir. 1970)
(Aralen); Basko v. Sterling Drug, Inc., 416 F.2d 417, 426 (2d Cir. 1969) (Aralen);
Parke-Davis & Co. v. Stromsodt, 411 F.2d 1390, 1400 (8th Cir. 1969) (Quadrigen);
Davis v. Wyeth Laboratories, Inc., 399 F.2d 121, 130 (9th Cir. 1968) (polio vaccine).
64. See, e.g., letters from Ortho Pharmaceutical Corp., Feb. 1, 1967, from Mead
Johnson Laboratories, June 30, 1967, from Syntex, Jan. 22, 1968 in MINTZ, supra
note 15 at 119-22, app. A.
65. See note 59 & accompanying text supra.
66. Sterling Drug, Inc. v. Yarrow, 408 F.2d 978, 994 (8th Cir. 1969) (Aralen).
67. See cases cited note 63 supra.
68. 416 F.2d 417 (2d Cir. 1969).
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dence bearing upon timeliness of the manufacturer's warning was not
introduced.60 Nevertheless, given the manufacturers' delay in respond-
ing to the evidence of danger in oral contraceptives, 70 pill manufac-
turers could be found to have breached the duty to warn under the
timeliness doctrine of Basco.
The Product Card and Physician's Desk Reference
The statements in the product card and the Physician's Desk Ref-
erence are virtually identical. 1, The information contained in the prod-
uct card, which must always accompany the drug, is regulated by the
FDA.72 The Physician's Desk Reference contains the manufacturer's
statements describing drugs on the market and is mailed free to every
doctor each year.
Since both of these sources usually provide the doctor with in-
formation concerning properties of a drug, a total absence of warning
in this literature may be a breach of the duty to warn. 73 An inade-
quate warning in this literature may also breach the manufacturer's
duty to warn.74 Moreover, a change of the warning on the product
card may not be deemed sufficient to make the doctor aware of the
new dangers. 75 In Sterling Drug, Inc. v. Cornish76 there was evidence
that the manufacturer did change the product card to reflect newly dis-
covered dangers of the drug. A jury verdict could nevertheless be sus-
tained against the manufactuier from evidence that the doctor did not
regularly refer to these product cards.
77
Carmichael v. Reitz78 upheld the birth control pill manufacturer's
warning as adequate. The litigated warning was that used by G. D.
Searle & Co. in 1963. But for the following reason, it is contended
that the warning was not adequate. Eight manufacturers received
approval to market their respective drugs, each with different label-
ing.79  Some brands with identical chemical formulas had different
69. Carmichael v. Reitz, 17 Cal. App. 3d 958, 989, 95 Cal. Rptr. 381, 400 (1971)
(Enovid).
70. See text accompanying notes 8-32 supra.
71. The court received the manufacturer's product literature in lieu of a state-
ment from the Physician's Desk Reference. Carmichael v. Reitz, 17 Cal. App. 3d
958, 990, 95 Cal. Rptr. 381, 401 (1971).
72. 21 U.S.C. § 352 (1970).
73. Abbott Laboratories v. Lapp, 78 F.2d 170 (7th Cir. 1935).
74. See note 48 supra.
75. Sterling Drug, Inc. v. Yarrow, 408 F.2d 978 (8th Cir. 1969) (Aralen); Ster-
ling Drug, Inc. v. Cornish, 370 F.2d 82 (8th Cir. 1966) (Aralen).
76. 370 F.2d 82 (8th Cir. 1966) (Aralen).
77. Id. at 84. "
78. 17 Cal. App. 3d 958, 990, 95 Cal. Rptr. 381, 401 (1971).
79. WILLiAms, supra note 3, at 31. -.
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side effects listed because different reactions had been reported to the
respective company marketing the same drug."° It was not until 1967
that the FDA imposed uniform labeling for all brands.sl Prior to the
uniform labeling, however, since the warning varied with the drug
company, and not with the ingredients, it could not be considered
adequate.
In summary, the product card is required to accompany prescrip-
tion drugs and is a vital source of information for the prescribing doc-
tor. The Physician's Desk Reference serves the prescribing doctor in a
similar manner, since it is a yearly compilation of the information
contained on drug package inserts. Liability may arise if the manu-
facturer has breached its duty to warn adequately in this literature.
Moreover, the manufacturer has a duty to do more than merely change
its product card information when new dangers associated with the
drug are discovered-it must bring home the new dangers to the doc-
tor.
Warning to the User
Physician's Warning to Patient Inadequate
The law is clear that the manufacturer must warn the prescrib-
ing doctor of the hazards associated with use of the newly marketed
drug,8 2 and most courts hold that an adequate warning to the doctor
is a sufficient warning as a matter of law.8 3  This exception to the
general requirement of a warning to the consumers4 is made be-
cause the intermediary, the doctor, is not a mere conduit of informa-
tion concerning the product, but rather one primarily obligated to in-
form the consumer because he administers or recommends the drug.8"
The doctor has been characterized as the "learned intermediary" be-
tween the purchaser and manufacturer. "  Explaining the doctor's
role in Steirling Drug, Inc. v. Corn ish87 the court said in dicta:
If the doctor is properly warned of the possibility of a side effect
in some patients, and is advised of the symptoms normally accom-
80. Id.
81. Id. The uniform labeling has also been criticized for weakness and ambi-
guity.
82. See text accompanying notes 47-52 supra.
83. E.g., Basko v. Sterling Drug, Inc., 416 F.2d 417 (2d Cir. 1969) (Aralen);
Stottlemire v. Cawood, 213 F. Supp. 897 (D.D.C. 1963) (chloromycetin); Carmichael
v. Reitz, 17 Cal. App. 3d 958, 95 Cal. Rptr. 381 (1971) (Enovid).
84. W. PROSSER, LAW OF TORTS § 96, at 648-49 (4th ed. 1971).
85. Sterling Drug, Inc. v. Cornish, 370 F.2d 82, 85 (8th Cir. 1966) (Aralen);
Krug v. Sterling Diug, Inc., 416 S.W.2d 143, 151 (Mo. 1967) (Aralen).
86. Sterling Drug, Inc. v. Cornish, 370 F.2d 82, 85 (8th Cir. 1966).
87. 370 F.2d 82, 85 (8th Cir. 1966).
THE HASTINGS LAW JOURNAL [Vol. 23
BIRTH CONTROL PILL. MANUFACTURERS
panying the side effect, there is an excellent chance that injury to
the patient can be avoided.38
The view that an adequate warning to the doctor relieves the drug
manufacturer of liability for subsequent injury or death is based on
the fact that
(1) the doctor is intended to be an intervening party in the full
sense of the word. Medical ethics as well as medical practice dic-
tate independent judgment, unaffected by the manufacturer's con-
trol, on the part of the doctor. (2) Were the patient to be given
the complete and highly technical information on the adverse pos-
sibility associated with the use of the drug, he would have no way
to evaluate it, and in his limited understanding he might actually
object to the use of the drug, thereby jeopardizing his life. (3) It
would be virtually impossible for a manufacturer to comply with
the duty of direct warning, as there is no sure way to reach the
patient.
8 9
These arguments should not apply to the marketing and use of
birth control pills because the pills are unlike ordinary prescription
drugs in several respects-publicity, resultant consumer demand, and
mass consumption not intended for the treatment of illness. Patients
have been eager to take the pill and have specifically requested it9 as
the most effective means of preventing unwanted pregnancies.9 1 Oral
contraceptives were widely publicized with little attention given to
adverse effects;9 2 doctors therefore prescribed them. 3
The view that an adequate explanation to the doctor exculpates
the drug manufacturer applies to drugs which treat an existing illness
88. Id.
89. Rheingold, Products Liability-The Ethical Drug Manufacturer's Liability,
18 RuTGERS L. Rv. 947, 987 (1964), cited with approval in Carmichael v. Reitz,
17 Cal. App. 3d 958, 989, 95 Cal. Rptr. 381, 400-01 (1971) (Enovid).
90. "A particularly serious matter to the clinician, the contraceptive pill is un-
like any other drug that he prescribes. Not only does it cast him into an unfamiliar
role of preventing a natural creative process rather than a disease, but it places him
at the mercy of directors who are not always in agreement on how the play is to be
enacted. The initiative is obviously not his but the patient's." Editorial, 206 J.A.M.A.
124 (1968) (emphasis added).
91. The failure rate of the interuterine device has not yet been fully determined,
but it is a less effective contraceptive than the pill which is almost 100% effective. To
date, 50% of the women who use the I.U.D. have it removed within two years. Segal
and Lietz, Contraceptive Technology, Current and Perfected Methods, Reports of Pop-
ulation Family Planning, in POPULATION CouNcIL AND INTERNATIONAL INSTITUTE FOR
THE STUDY OF HUmAN REPRODUCTION 7, 9 (1969).
The failure rate for the diaphragm is 12% (that is, of 100 women using the
diaphragm in a year, 12 women become pregnant). The failure rate for the condom
is 14%. E. HANAmANN, A SPEcIAL REPORT 159 (1967).
92. See text accompanying note 18 supra.
93. See note 90 supra.
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in which the doctor must weigh the risks of the use of the drug on the
patient against the harm the illness will cause the patient. Since the
general use of birth control pills applies to prevent pregnancy, however,
the balancing of risks would not apply if the prescribing doctor had
determined that pregnancy would harm his patient. Even if it were de-
termined that pregnancy presented a danger to his patient, the doc-
tor should consider other forms of birth control in weighing benefits
and risks; the oral contraceptive is only one of many types of birth con-
trol methods.
94
The argument that direct warning from drug manufacturer to con-
sumer is impossible is not applicable to the marketing of birth con-
trol pills. In fact, direct warning to the consumer is now required by
the FDA.95 The court in Carmichael v. Reitz,96 in approving the
warnings on birth control pills, cited the impossibility of direct warn-
ings and the doctor's responsibility to disclose the dangers to his pa-
tient. In Carmichael, however, the pill was not prescribed as a birth
control device, but as chemotherapy for endrometriosis, heavy and
painful menstrual flow (dysmenorrhea) and as an aid to achieving
pregnancy. 97  Accordingly, the doctor weighed the dangers to the pa-
tient's health against the then revealed dangers of the pill to his pa-
tient.98  The doctor's independent judgment, and the patient's inability
to comprehend the medical and technical complexities of her doctor's
decision, make exculpation of the drug manufacturer, despite a breach
of duty to warn the consumer, appropriate under the distinguishable
facts of the Carmichael case. Carmichael did not, however, deal
with the usual situation in which demand for the oral contraceptive
was created by its manufacturer's unobjective marketing in which lit-
tle attention was paid to inherent dangers in the drug's use and its rea-
soning should not apply in such cases.
Few prescription drug decisions consider the manufacturer's duty
to warn the public. In Stottlemire v. Cawood99 the plaintiff alleged that
chloromycetin, an antibiotic, caused aplastic anemia which killed a
four year old child. The court held that since the drug could only
94. See note 91 supra.
95. See text accompanying note 29 supra.
96. 17 Cal. App. 3d 958, 989, 95 Cal. Rptr. 381, 400-01 (1971) (Enovid).
97. Id. at 972, 95 Cal. Rptr. at 388. Medical testimony at the trial revealed
that endrometriosis is a disease in which tissue normally lining the inner surface of the
uterus invades the pelvic area where it forms cysts and lesions. If untreated, it can
lead to cancer and blockage of the colon, both life threatening conditions. Brief for
Respondent at 3, Carmichael v. Reitz, 17 Cal. App. 3d 958, 95 Cal. Rptr. 381 (1971).
98. The prescribing doctor testified that at the time he prescribed Enovid, 1964,
pulmonary embolism (blood clots in the lung) was not recognized to be an adverse
reaction in the medical community. 17 Cal. App. 3d at 973, 95 Cal. Rptr. at 389.
99. 213 F. Supp. 897 (D.D.C. 1963).
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be obtained via doctor's prescription, "there was no reason why there
should be a warning of any dangerous possibilities given to the general
public."'100 A different rule applies to over-the-counter drugs.101
In Carmen v. Eli Lilly & Co., where the decedent had taken a rabies
vaccine at the urging of a public health doctor who purchased it for
the decedent, the court held there was a duty upon the manufacturer
to warn the patient-consumer.102  The duty arose because the decedent
could have purchased the vaccine without a prescription in any drug
store.103
Magee v. Wyeth Laboratories, Inc.,10 4 involving drugs adminis-
tered by a doctor without voluntary selection by the patient, held there
is no duty on the part of the manufacturer to warn the patient. In
Magee, Sparine, a tranquilizer used to calm an hysterical patient, was
administered by needle. In holding that an adequate warning to the
physician absolves the manufacturer from any liability in warranty,105
the court, in dicta, determined that
[rjeliance upon the alleged warranty is essential to plaintiffs' cause
of action. . . and there is no basis for an inference that Mr. Magee
had any voluntary part in the selection or use of this drug, no
opportunity for reliance upon the warranty and no reliance in
fact.' 0
6
It seems a permissible inference from this language that if the patient
voluntarily chooses to take the drug, relying on the manufacturer's war-
ranty of fitness, the manufacturer may incur liability to the patient for
its breach. 10 7  Since most women taking birth control pills have vol-
100. Id. at 899.
101. A drug manufacturer who manufactures and distributes an article, which,
if improperly used, is dangerous to human life, is under a duty to warn the public, by
labels or otherwise, of the manner in which the drug may be safely used. Martin v.
Bengue, Inc., 25 N.J. 359, 136 A.2d 626 (1957) ("Ben-Gay" ointment); Marcus v. Spe-
cific Pharmaceuticals, Inc., 82 N.Y.S.2d 194 (Sup. Ct. 1948) (drug not named).
102. Carmen v. Eli Lilly & Co., 109 Ind. App. 78, 87, 32 N.E.2d 729, 732 (1941).
The irony of this case is that the rabies vaccine is often used as an example of a
highly dangerous prescription drug. RESTATEMENT (SECOND) OF ToRTs, Explanatory
Notes, § 402A, comment k at 453 (1964).
103. 109 Ind. App. at 87, 32 N.E.2d at 732.
104. 214 Cal. App. 2d 340, 29 Cal. Rptr. 322 (1963). The plaintiff alleged
breach of an implied warranty in that the drug was not fit for human consumption.
105. The standards for an adequate warning are identical in theories of negli-
gence, strict liability, and warranty. Basko v. Sterling Drug, Inc., 416 F.2d 417, 427
(2d Cir. 1969) (Aralen). See Prosser, The Fall of the Citadel (Strict Liability to the
Consumer), 50 MINN. L. REv. 791, 808 (1966).
106. Magee v. Wyeth Laboratories, Inc., 214 Cal. App. 2d 340, 352, 29 Cal.
Rptr. 322, 329 (1963).
107. Toole v. Richardson-Merrell, Inc., 251 Cal. App. 2d 689, 708, 60 Cal. Rptr.
398, 412 (1967) (MER/29). The elements necessary for a cause of action in im-
plied warranty were found when the plaintiff had purchased the prescription drug as
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untarily selected this method of contraception, manufacturer liability
should result from the inadequate warning to consumers of oral con-
traceptives.
Oral Polio Vaccine Cases
The cases involving oral doses of polio vaccine'0 8 present a
strong analogy to the birth control situation. In these cases, the manu-
facturer sold the vaccine to a medical society. The medical society
sponsored a community immunization program, dispensing the oral
vaccine to all participants. In two of the cases, the manufacturers
had given no warning to the immunization campaign sponsors that
the vaccine caused polio in one out of every million adult users. 109
Neither considered whether the manufacturer also had a duty to
warn consumers of this risk. In the case of Davis v. Wyeth Labora-
tories, Inc., however, though the manufactuer had warned the cam-
paign sponsors of this risk, the court concluded that the manufacturer
breached its duty by failing to warn the consumer as well. 110
The Davis court distinguished the oral polio vaccine from other
prescription drugs because of the manner in which it was dispensed"'
-at mass clinics without an individualized balancing of risks where the
manufacturer knew that the warnings given to the medical society were
not reaching the consumer. A similar distinction should be made by
the courts with respect to the marketing of birth control pills because
the consumer is not being reached by manufacturer's warnings. 11 2 Both
the vaccine and birth control pill manufacturers took an active part
in encouraging wide spread use of the drug through nationwide ad-
vertising.113  In addition, marketing of both the birth control pill and
recommended by the doctor. The drug was capable of causing harmful side effects
when taken as recommended, and plaintiff's injuries were caused by the drug. See gen-
erally Spangenberg, Aspects of Warranties Relating to Defective Prescription Drugs,
37 U. COLO. L. REv. 194 (1965).
108. Davis v. Wyeth Laboratories, Inc., 399 F.2d 121 (9th Cir. 1968); Grinnell
v. Charles Pfizer & Co., 274 Cal. App. 2d 424, 79 Cal. Rptr. 369 (1969); Stahlheber
v. American Cyanamid Co., 451 S.W.2d 48 (Mo. 1970). Two more cases involved the
polio vaccine, but it was administered by a private doctor on an individual basis.
Berry v. American Cyanamid Co., 341 F.2d 14 (6th Cir. 1965); Gottsdanker v. Cutter
Laboratories, 182 Cal. App. 2d 602, 6 Cal. Rptr. 320 (1960).
109. Grinnell v. Charles Pfizer & Co., 274 Cal. App. 2d 424, 439, 79 Cal. Rptr.
369, 377 (1969); Stahlheber v. American Cyanamid Co., 451 S.W.2d 48, 59 (Mo.
1970).
110. Davis v. Wyeth Laboratories, Inc., 399 F.2d 121, 130 (9th Cir. 1968).
111. Id. at 131.
112. See note 28 supra. If injury to the patient-consumer occurred after the
FDA warning was attached to the birth control pills, the plaintiff would have to prove
an inadequate warning in order to recover.
113. In Love v. Wolf, 226 Cal. App. 2d 378, 394, 38 Cal. Rptr. 183,
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oral polio -vaccine can be distinguished from other prescription drugs
because a warning to the medical profession was not the most ef-
fective way of. permitting the healthy patient to make an intelligent
choice about whether or not to take the drug. Accordingly, failure
to warn consumers of the adverse effects of oral contraceptives should
result in liability of the manufacturer for injuries sustained by consump-
tion of these dangerous drugs.
Strict Liability for Unforeseen Side Effects
Assuming that a birth control pill manufacturer has given an
adequate warning of the harmful side effects of the drug to the doctor
and consumer, the issue remains whether strict liability would permit
a recovery for unforeseen side effects.
The theory of strict liability in tort has virtually superseded the
concept of implied warranty," 4 although the basic elements to be
proved are the same. The rule of strict liability is articulated in
Greenman v. Yuba Power Products, Inc.:
A manufacturer is strictly liable in tort when an article he places
on the market, knowing that it is to be used without inspection
for defects, proves to have a defect that causes injury to a human
being. 1
15
The Second Restatement of Torts, section 402A, comment k, makes an
important exception to strict liability for certain kinds of products:
k. Unavoidably unsafe products. There are some products
which, in the present state of human knowledge, are quite in-
capable of being made safe for their intended and ordinary use.
These are especially common in the field of drugs. An outstanding
example is the vaccine for the Pasteur treatment of rabies, which
not uncommonly leads to very serious and damaging consequences
when it is injected. Since the disease itself invariably leads to a
dreadful death, both the marketing and the use of the vaccine
are fully justified, notwithstanding the unavoidable high degree of
risk which they involve. Such a product, properly prepared, and
accompanied by proper directions and warning, is not defective,
nor is it unreasonably dangerous. The same is true of many other
drugs, vaccines, and the like, many of which for this very reason
cannot legally be sold except to physicians, or under the prescrip-
tion of a physician. It is also true in particular of many new or
experimental drugs as to which, because of lack of time and oppor-
tunity for sufficient medical experience, there can be no assurance
195 (1964), the profit from the sale of the drug was held admissible to show that
the drug was used for more than the limited purposes recommended by experts.
114. Greenman v. Yuba Power Prod., Inc., 59 Cal. 2d 57, 63, 377 P.2d 897,
901, 27 Cal. Rptr. 697, 701 (1963); Prosser, The Fall of the Citadel (Strict Liability to
the Consumer), 50 MINN. L. REv. 791, 804-05 (1966).
115. 59 Cal. 2d at 62, 377 P.2d at 900, 27 Cal. Rptr. at 700.
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of safety, or perhaps even of purity of ingredients, but such ex-
perience as there is justifies the marketing and use of the drug
notwithstanding a medically recognizable risk. The seller of such
products, again with the qualification that they are properly pre-
pared and marketed, and proper warning is given, where the situ-
ation calls for it, is not to be held to strict liability for unfortunate
consequences attending their use, merely because he has under-
taken to supply the public with an apparently useful and desirable
product, attended with a known but apparently reasonable risk.
(Emphasis added)
Many courts have cited comment k with approval as applicable to
all prescription drugs." 6  Accordingly, if the drug is properly pre-
pared and accompanied by proper directions and warnings, the manu-
facturer is not liable for harmful side effects under the Restatement
theory. An examination of how the courts have applied comment k
to prescription drug cases, however, permits the assertion that birth
control pills should not fall within the exception to strict liability pro-
vided by this section.
Lewis v. Baker" 7 involved MER/29, a drug developed for the
purpose of lowering blood cholesterol levels. The court cited com-
ment k as an appropriate standard for the imposition of strict liability.
In defining a drug not "unreasonably dangerous" according to com-
ment k, the Oregon Supreme Court held that a prescription drug, "prop-
erly tested, labeled with appropriate warnings, approved by the Food
and Drug Administration, and marketed properly under federal reg-
ulation, is, as a matter of law, a reasonably safe product."' 18  The
plaintiff could not recover for cataracts caused by MER/29 because
he could prove neither impurity in the drug nor deviation from FDA
labeling standards. The court essentially held that approval by the
FDA established a reasonably safe product." 9 However, the Lewis
decision stands alone in contending that meeting FDA standards ex-
culpates the manufacturer. Subsequent cases have examined the ade-
quacy of the warning, independent of FDA approval. 20
A drug must be defective to fall within the scope of strict li-
116. E.g., Davis v. Wyeth Laboratories, Inc., 399 F.2d 121, 127-28 (9th Cir.
1968) (polio vaccine); Carmichael v. Reitz, 17 Cal. App. 3d 958, 988, 95 Cal. Rptr.
381, 399-400 (1971) (Enovid); Toole v. Richardson-Merrell, Inc., 251 Cal. App. 2d
689, 708, 60 Cal. Rptr. 398, 412 (1967) (MER/29).
117. 243 Ore. 317, 413 P.2d 400 (1966), discussed in Keeton, Some Observa-
tions About the Strict Liability of the Maker of Prescription Drugs: The Aftermath
of MER/29, 56 CALIF. L. REV. 149, 153-54 (1968).
118. 243 Ore. 317, 324, 413 P.2d 400, 404 (1966).
119. Id.
120. E.g., Basko v. Sterling Drug, Inc., 416 F.2d 417 (2d Cir. 1969) (Aralen);
Magee v. Wyeth Laboratories, Inc., 214 Cal. App. 2d 340, 29 Cal. Rptr. 322 (1963)
(Sparine). See cases collected in Annot. 79 A.L.R.2d 301 (1961).
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ability. 2' The harmful side effect inherent in the drug is the defect.'
22
Though the drug was manufactured in the manner intended, it is dan-
gerous, and thus defective for strict liability purposes. The oral contra-
ceptive is a "defective product" in the strict liability sense of the term.
In Oresman v. G. D. Searle & Co.,'23 involving injury from the use of
birth control pills, the court held that
[t]o entitle plaintiffs to a recovery under this doctrine [strict lia-
bility], they need only establish by the required degree of proof that
said birth control pills were manufactured by the defendant, that
they were defective and that their defects caused the stroke alleged
in said Count.
124
The court made no attempt to define "defective" and refused to rule
that birth control pills were "unavoidably unsafe products"'1 5 unless
defendant could produce probative evidence to that effect.' 26 The
Carmichael court, on the other hand, following comment k of Restate-
ment section 402A, reasoned that birth control drugs are exempt from
strict liability if evidentiary facts disclose that the drug was properly
prepared and sold with adequate warnings.'
27
Comment k can be seen to serve two purposes. First, it permits
treatment of serious illness with high risk drugs without imputing strict
liability to the manufacturer. The example of Pasteur's rabies treat-
ment is cited in comment k to illustrate the balancing of risks between
"dreadful death" from rabies and "very serious and damaging conse-
quences" from the treatment. The birth control pill, however, is only
121. See text accompanying note 115 supra.
122. Davis v. Wyeth Laboratories, Inc., 399 F.2d 121, 128 (9th Cir. 1968)
(polio vaccine). See Toole v. Richardson-Merrell, Inc., 251 Cal. App. 2d 689, 711, 60
Cal. Rptr. 398, 414 (1967).
123. 321 F. Supp. 449 (D.R.I. 1971).
124. Id. at 456.
125. Id. at 457. The court cited the RaSTATEMENT (SECOND) OF TORTS § 402A
(1), (2) (1965): "402 A. Special Liability of Seller of Product for Physical Harm
to User or Consumer. (1) One who sells any product in a defective condition unrea-
sonably dangerous to the user or consumer or to his property is subject to liability for
physical harm thereby caused to the ultimate user or consumer, or to his property, if
"(a) the seller is engaged in the business of selling such a product, and
"(b) it is expected to and does reach the user or consumer without substantial
change in the condition in which it is sold.
(2) The rule stated in Subsection (1) applies although
"(a) the seller has exercised all possible care in the -preparation and sale
of his product, and
"(b) the user or consumer has not bought the product from or entered into
any contractual relation with the seller."
126. 321 F. Sapp. at 457.
127. Carmichael v. Reitz, 17 Cal. App. 3d 958, 988-89, 95 Cal. Rptr. 381, 400
'(1971), citing Toole v. Richardson-Merrell, Inc., 251 Cal. App. 2d 689, 60 Cal.
Rptr. 398 (1967).
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one method of contraception among an expanding group of less dan-
gerous alternatives. In the ordinary case, on demand from the patient,
the pill is prescribed as the most effective means of preventing preg-
nancy, just as the last-ditch treatment of an otherwise terminal disease.
The second purpose of comment k is to permit drug manufactur-
ers to experiment on human beings with new drugs without incurring
liability for failure or unanticipated side effects. The effect of com-
ment k, however, may be too harsh on the injured user. In Cunning-
ham v. MacNeal Memorial Hospital128 a hospital incurred liability for
dispensing blood containing serum hepatitus virus, even though hepa-
titus virus is undetectable in blood. In Cunningham, comment k was
interpreted as applying to drugs which involve substantial inherent risk
of injury, but not to those containing impuirty. -12 9  The distinction be-
tween an undetectable impurity and an inherently harmful effect seems
semantic; the risk of harm to the patient is equally unforeseeable.
Christofferson v. Kaiser Foundation Hospitals'" considered the
extent of the manufacturer's liability for unforeseen side effects. The
California court considered drugs causing "direct results," i.e., those
causing the very disease against which they were designed to protect,
as within strict liability. The manufacturer of a drug causing a side
effect which was unrelated to the purpose of the drug, however, was
distinguished; its liability is limited by comment k.1' Limited liability
under comment k for defendant drug companies is thus being eroded
through judicial decisions such as Cunningham and Christofferson.
Comment k of Restatement section 402A appears to remove cer-
tain prescription drugs from the ambit of strict liability. The manu-
facturer's duty, when comment k applies, is merely one of avoiding
ordinary negligence by proper preparation, directions and warnings.
As has been stated, however, since birth control pills generally do
not treat serious illness, one of the rationales for comment k does not
apply to these drugs. Moreover, new drug research on human beings
without attendant manufacturer liability for resulting injuries has been
questioned by several authors.132 The result of this questioning is a
series of confusing opinions grasping at semantic distinctions to avoid
128. 47 Il. 2d 443, 266 N.E.2d 897 (1970).
129. Id. at 456, 266 N.E.2d at 904.
130. 15 Cal. App. 3d 75, 78, 92 Cal. Rptr. 825, 826 (1971) (dictum) (Aralen).
131. Id. at 79, 92 Cal. Rptr. at 826.
132. Louisell, The Liability of the Drug Manufacturer for Drug Reactions, in
DRUG LIABILITY LITIGATION 169, 181 (E. Shapiro, R. Needham & J. Feldman, eds.
1967); James, The Untoward Effects of Cigarettes and Drugs: Some Reflections on
Enterprise Liability, 54 CALIF. L. REV. 1550, 1557 (1966); Keeton, Some Observations
About the Strict Liability of the Maker of Prescription Drugs: The Aftermath of
MER/29, 56 CALIF. L. REV. 149, 153 (1968).
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applying comment k. The court in Cunningham, for example, re-
moved drugs containing "undetectable impurities" from the comment
k no strict liability rule. 33 In addition, the Christofferson court ap-
plied strict liability, notwithstanding comment k, to drugs which
caused the disease they were designed to prevent.' 34 This analysis of
comment k permits the conclusion that it should not apply to harmful
side effects resulting from an inherent defect in birth control pills.
Conclusion
Under commonly accepted theories of tort liability, a prescription
drug manufacturer is liable to a consumer for injuries only if the man-
ufacturer failed to adequately warn the prescribing doctor about the
risks of the drug. Birth control pills, however, should be treated sep-
arately from ordinary prescription drugs. The FDA failed to regulate
contraceptive advertisement with the result that the demand for oral
contraceptives swelled. Birth control pills are thus unlike other pre-
scription drugs in that patients generally demanded the drug.
Birth control pills should also be distinguished from ordinary
prescription drugs in a second sense. They do not treat existing ill-
ness but rather constitute one method of preventing pregnancy. Nor-
mally, special tort theories are applied to prescription drugs because
of the balancing of risks and benefits of drug use against the gravity
of an illness to determine whether the risks of the drug use outweighs
the possible consequences of the illness thus treated. Since oral con-
traceptive use normally does not involve illness treatment, these stand-
ards should not apply to birth control pills.
A drug manufacturer is also liable to the patient for injuries re-
suiting from the drug's use if it fails to adequately warn the medical
profession of the known side effects of the drug. No warning to the
consumer is usually required. In the case of oral contraceptives, how-
ever, the manufacturer should be required to go at least one step fur-
ther and warn the consumer of known risks. Warning only the physi-
cian has been justified on the theory that the prescribing practitioner
will inform the consumer of the risks of ingesting the drug, but pa-
tients have not received the necessary information from their doctors
concerning the risks of the use of birth control pills. Moreover, cases
involving the oral polio vaccine provide a strong basis for the argu-
ment that birth control manufacturers should be required to directly
warn the consumer of dangerous side effects. The polio vaccine is a
133. Cunningham v. MacNeal Memorial Hosp., 47 111. 2d 443, 456, 266 N.E.2d
897, 904 (1970).
134. Christofferson v. Kaiser Foundation Hosps., 15 Cal. App. 3d 75, 78, 92 Cal.
Rptr. 825, 826 (1971) (dictum) (Aralen).
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publicly advertised prescription drug; the vaccine is ingested as a pre-
ventative measure, not to treat illness. In Davis a polio vaccine manu-
facturer incurred liability for failing to warn consumers of the actual
statistical risk of ingestion-one death among each million users.
Warning to the medical profession in that case was deemed inadequate
because the warning was not reaching consumers. The duty to fully
inform birth control pill consumers of dangerous side effects should
be similarly imposed on drug manufacturers.
Assuming that a drug manufacturer has given adequate warning
of known side effects, the manufacturer should still incur liability for
unforeseen side effects. The Restatement of Torts, section 402A,
comment k, asserts that prescription drug manufacturers should not be
liable for defective products. Comment k places full responsibility
upon the physician to weigh risks and benefits in the prospective use
of a prescription drug and the example of a highly dangerous treat-
ment for a serious illness is cited. This reasoning, however, does not
apply to the use of birth control pills because the drug is not used to
treat serious illness.
In addition, comment k permits the drug manufacturer to ex-
periment on humans without incurring liability, but the courts ap-
pear reluctant to place the full burden of injury upon the user. The
comment k standard has been held not applicable to certain categories
of prescription drugs; strict liability is applied to "impure drugs" and
to drugs causing the disease they are intended to prevent. These un-
warranted distinctions should be set aside and strict liability should ap-
ply to birth control pills.
The use of birth control pills can be seen as an uncontrolled ex-
periment with disasterous consequences for some of its participants.
Because of ineffective warnings to the user, many women unknowingly
risk death or serious injury to prevent conception. Drug manufactur-
ers must accept legal responsibility for the occasional disasterous con-
sequences of this experiment.
Sandra Blair*
* Member, Second Year Class
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